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The molecular mechanisms controlling bone extracellular matrix (ECM) deposition by differentiated
osteoblasts in postnatal life, called hereafter bone formation, are unknown. This contrasts with the growing
knowledge about the genetic control of osteoblast differentiation during embryonic development. Cbfa1, a
transcriptional activator of osteoblast differentiation during embryonic development, is also expressed in
differentiated osteoblasts postnatally. The perinatal lethality occurring in Cbfa1-deficient mice has prevented
so far the study of its function after birth. To determine if Cbfa1 plays a role during bone formation we
generated transgenic mice overexpressing Cbfa1 DNA-binding domain (DCbfa1) in differentiated osteoblasts
only postnatally. DCbfa1 has a higher affinity for DNA than Cbfa1 itself, has no transcriptional activity on its
own, and can act in a dominant-negative manner in DNA cotransfection assays. DCbfa1-expressing mice have
a normal skeleton at birth but develop an osteopenic phenotype thereafter. Dynamic histomorphometric
studies show that this phenotype is caused by a major decrease in the bone formation rate in the face of a
normal number of osteoblasts thus indicating that once osteoblasts are differentiated Cbfa1 regulates their
function. Molecular analyses reveal that the expression of the genes expressed in osteoblasts and encoding
bone ECM proteins is nearly abolished in transgenic mice, and ex vivo assays demonstrated that
DCbfa1-expressing osteoblasts were less active than wild-type osteoblasts. We also show that Cbfa1 regulates
positively the activity of its own promoter, which has the highest affinity Cbfa1-binding sites characterized.
This study demonstrates that beyond its differentiation function Cbfa1 is the first transcriptional activator of
bone formation identified to date and illustrates that developmentally important genes control physiological
processes postnatally.
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Bone extracellular matrix (ECM) deposition or bone for-
mation by differentiated osteoblasts starts late during
development and lasts throughout life. This is a totally
different process than bone development, which is char-
acterized by cell commitment and differentiation. The
bone ECM contains two types of proteins: the collagens,
mostly type I collagen, which account for 90% of the
bone matrix proteins (Gehron-Robey 1996), and the non-
collagenous proteins, including osteocalcin, osteopon-
tin, and bone sialo protein (Hauschka et al. 1989; Bianco
et al. 1991; Denhardt and Guo 1993). Postnatally the
production of bone ECM by osteoblasts must be regu-
lated tightly to allow skeleton growth to occur and to
replace bone resorbed by the osteoclasts throughout life
(Ott 1996). Defective bone formation by the osteoblasts
is at the origin of crippling and frequent genetic diseases
such as osteogenesis imperfecta (Prockop and Kivirikko
1984; Byers 1990; Rowe and Shapiro 1998), and of ac-
quired diseases like osteoporosis, the most frequent
metabolic bone disease (Kleerekoper and Avioli 1998). In
the United States only, >1 million osteoporotic fractures
are diagnosed each year, resulting in substantial morbid-
ity and mortality. This rate, which is expected to accel-
erate because of the unprecedented increase in life ex-
pectancy, exemplifies the importance of identifying mo-
lecular regulators of bone formation.
Cbfa1 is the only osteoblast-specific transcription fac-
tor identified to date. Molecular and genetic evidence
have demonstrated that it acts as an activator of osteo-
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blast differentiation during embryonic development in
mouse and human. Indeed, Cbfa1 is expressed in cells of
the osteoblastic lineage during development, it regulates
osteoblast-specific expression of Osteocalcin and Osteo-
pontin, can induce osteoblastic differentiation of nonos-
teoblastic cells (Ducy et al. 1997), and patients hetero-
zygous for mutations or deletions of CBFA1 develop clei-
docranial dysplasia (CCD) (Lee et al. 1997; Mundlos et al.
1997). Likewise, inactivation of Cbfa1 in mice leads to a
total absence of osteoblasts in homozygous mutant ani-
mals, and to a CCD phenotype in heterozygous mutant
animals (Komori et al. 1997; Otto et al. 1997). Thus
Cbfa1 is an indispensable regulator of osteoblast differ-
entiation that fullfills a function dominant to and nonre-
dundant with the function of any other gene product.
This progress in our understanding of osteoblast dif-
ferentiation during development has left unanswered a
major question of skeleton biology, namely: What are
the molecules controlling bone formation once osteo-
blast differentiation has occured? This lack of knowledge
about the regulation of bone formation contrasts also
with the growing body of information regarding the con-
trol of osteoclastic bone resorption (Soriano et al. 1991;
Simonet et al. 1997; Bucay et al. 1998; Lacey et al. 1998;
Yasuda et al. 1998).
Two correlative arguments suggest that Cbfa1 may be
involved in postnatal bone formation. First, Cbfa1 is ex-
pressed at high levels in osteoblasts after birth (Ducy et
al. 1997). Second, it regulates the in vitro and in vivo
expression of Osteocalcin (Ducy et al. 1997; Frendo et al.
1998), a gene virtually not expressed before birth and
that is the hallmark of the differentiated osteoblast phe-
notype (Owen et al. 1990; Stein et al. 1990; Aubin and
Liu 1996). For these reasons, we decided to test whether
Cbfa1 is a determinant of bone formation by differenti-
ated osteoblasts postnatally. This question could not be
answered in vivo until now because the deletion of
Cbfa1 leads to perinatal lethality in mice (Komori et al.
1997; Otto et al. 1997), and no juvenile or more severe
osteoporosis has been described in CCD patients. The
observation that haploinsufficiency at the Cbfa1 locus
causes CCD suggests that if Cbfa1 controls bone forma-
tion postnatally it should be possible to demonstrate this
by altering its level of expression and/or its function
postnatally. The availability of a cell-specific and stage-
specific promoter, such as the Osteocalcin promoter that
is not active before birth, provides us with an excellent
tool to address this question.
We show here, through a time-specific, cell-specific,
and stage-specific inhibition-of-function experiment
that Cbfa1 is required for bone formation by differenti-
ated osteoblasts after birth. By controlling its own ex-
pression positively Cbfa1 is at the top of a genetic cas-
cade regulating bone ECM deposition. Inhibition of this
autoregulatory loop in differentiated osteoblasts results
in an osteopenic phenotype caused by the near abolition
of expression of ECM-related genes, including type I
collagen-encoding genes, without any overt effect on os-
teoblast differentiation. These results uncover a tran-
scriptional pathway governing bone formation by differ-
entiated osteoblasts and identify Cbfa1 as the first tran-
scriptional activator of this process.
Results
DCbfa1 inhibits Cbfa1 transactivation function
in a dominant-negative manner
Cbfa1 is one of the three known mouse Cbfa genes (Bae
et al. 1992, 1995; Ogawa et al. 1993; Ducy et al. 1997). In
Western blot analysis an antiserum that recognizes all
three Cbfa proteins detected only Cbfa1 in calvaria os-
teoblasts (Fig. 1A, lane 5), thus indicating that Cbfa1 is
the only Cbfa protein detectable in osteoblasts, which is
consistent with the phenotype observed when the gene
is deleted.
It has been shown that the DNA-binding domain of
runt-related proteins has no detectable transactivation
function on its own (Bae et al. 1994; Aranson et al. 1997;
Tracey et al. 1998). Consistent with these observations,
Cbfa1 DNA-binding domain (DCbfa1) failed to transac-
tivate a reporter vector containing six OSE2 elements,
the Cbfa1-binding sites (Ducy and Karsenty 1995) in
COS cells that do not express any Cbfa genes (Kurokawa
et al. 1996) (Fig. 1B). In DNA cotransfection experiments
performed in ROS 17/2.8 osteoblastic cells that do ex-
press Cbfa1 (Ducy and Karsenty 1995), increasing
amount of DCbfa1 led to a threefold decrease of activity
of a reporter vector containing a 160-bp Osteocalcin pro-
moter fragment fused to the luciferase (luc) reporter gene
(Fig. 1C). The activity of this Osteocalcin promoter frag-
ment is partly dependent on the presence of one OSE2
element (Ducy and Karsenty 1995; Frendo et al. 1998).
These results demonstrate that DCbfa1 has no transac-
tivation ability on its own but can impair Cbfa1 trans-
activation function.
To define the molecular basis of this inhibition of tran-
scription we performed DNA-binding assays with wild-
type and truncated recombinant proteins. In the condi-
tion of electrophoretic mobility shift assay (EMSA)
GST–DCbfa1 had a higher affinity for OSE2 than the
full-length GST–Cbfa1 protein (Fig. 1D). Moreover the
DCbfa1–DNA complex was far more stable than the
Cbfa1–DNA complex (Fig. 1E). These data indicate that
the dominant-negative function of DCbfa1 is because of
its higher affinity for OSE2, and the higher stability of
the DCbfa1–DNA complex.
Absence of skeletal abnormalities in newborn mice
expressing DCbfa1 in a differentiated
osteoblast-specific manner
Osteocalcin is the most osteoblast-specific gene known
(Hauschka et al. 1989). Its expression is not only cell-
specific but also time- and stage-specific. Indeed, its ex-
pression is virtually absent before birth, is restricted to
differentiated osteoblasts able to produce a bone ECM,
and is absent in osteoblast progenitors (Owen et al. 1990;
Stein et al. 1990; Aubin and Liu 1996). Recently, we have
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shown that a 1.3-kb fragment of the mouse Osteocalcin
(OG2) promoter contains all the regulatory elements
necessary to confer differentiated osteoblast- and post-
natal-specific expression to a reporter gene in vivo
(Frendo et al. 1998). This Osteocalcin promoter fragment
constitutes a unique resource to address osteoblast func-
tion without affecting osteoblast differentiation.
To determine whether DCbfa1 affects osteoblastic
bone formation in vivo postnatally we generated a con-
struct containing DCbfa1 coding sequence under the
control of the 1.3-kb OG2 promoter (Fig. 2A) and used it
to generate transgenic mice. In these transgenic animals,
called thereafter DCbfa1-expressing mice, DCbfa1 was
expressed only in bone (Fig. 2B). Two different lines of
transgenic mice were generated, both lines had a similar
level of expression of the transgene (Fig. 2C) and identi-
cal results were obtained with their progenies. The
DCbfa1-expressing mice were phenotypically normal at
birth; had a normally mineralized skeleton, an indica-
tion that their osteoblasts are functional; had no features
characteristic of a CCD phenotype; and there was no
perinatal lethality (Fig. 2D). The bone histology of these
mice was also normal at birth (data not shown).
Postnatal osteopenia without osteoblast depletion
in DCbfa1-expressing mice
Within 2 weeks after birth the DCbfa1-expressing mice
developed a short stature phenotype (Fig. 3A). X-ray
analysis showed shorter and more lucent long bones
with thinner cortices, three features indicative of
bone loss (Fig. 3B,C). The short stature phenotype
was probably not caused by chondrocyte abnormalities
as the growth plate cartilage appeared histologically
and histomorphometrically indistinguishable between
wild-type and DCbfa1-expressing animals (Fig. 3D and
growth plate thickness: wild type = 228.26 ± 11.86 µm;
DCbfa1 = 232.97 ± 26.76 µm). Conventional histology in
both long bones and vertebrae showed a decreased
amount of trabecular bone and thinner cortices, confirm-
ing the existence of an osteopenia affecting the whole
bone in the DCbfa1-expressing mice (Fig. 3E–G). Inspec-
tion of the cells at high magnification following tolu-
idine blue staining showed that the osteoblasts had the
same morphology in wild-type and DCbfa1-expressing
mice. However, the thickness of the osteoid layer
was significantly thinner in DCbfa1-expressing mice
(Fig. 3H).
To determine if this osteopenic phenotype was attrib-
utable to a functional defect of differentiated osteoblasts
or to a decrease of the osteoblast number, static and dy-
namic histomorphometric analyses were performed over
a 10-day period (day 10 to 20 postnatal) using tetracyclin/
calcein, a marker of bone formation (Parfitt et al. 1987).
This dynamic analysis aims at recording all the histo-
logical abnormalities existing during this period. As
shown by the distance between the tetracyclin and cal-
cein labels there was a major decrease (three- to fourfold)
in the amount of newly formed bone in the DCbfa1-ex-
pressing mice compared to wild-type animals (Fig. 4A).
The rate of bone formation was indeed 70% reduced in
DCbfa1-expressing mice (Fig. 4B) and the osteoid thick-
ness, an indicator of bone matrix deposition in the pres-
ence of an unchanged mineralization rate, was decreased
significantly (Fig. 4C). Likewise, the bone volume was
reduced in the DCbfa1-expressing mice (Fig. 4D).
Figure 1. Characterization of DCbfa1 ac-
tivity in vitro. (A) Cbfa1 is the only detect-
able Cbfa expressed in osteoblasts. Western
blot analysis of nuclear extracts from COS
cells transfected with the empty vector (−,
lane 1), a Cbfa3 (lane 2), a Cbfa2 (lane 3), or
a Cbfa1 (lane 3) expression vector or from
calvaria (lane 5). The antiserum used recog-
nize all three Cbfa proteins (indicated by
white asteriks). (B) DNA cotransfections in
COS cells. Overexpression of DCbfa1 does
not transactivate an OSE2–luc chimeric
promoter construct, whereas overexpres-
sion of Cbfa1 does. (−) cotransfection with
the empty vector. (C) Osteocalcin 160-bp
promoter–luc activation by endogenous
Cbfa1 is inhibited by cotransfection of in-
creasing amounts of DCbfa1 in ROS 17/2.8
osteoblastic cells. (DBD) DNA-binding do-
main. (D) Different affinity of Cbfa1 and
DCbfa1 for OSE2. DNA competition in
EMSA were performed with identical
amount of GST–Cbfa1 or GST–DCbfa1, la-
beled OSE2, and increasing amounts of un-
labeled OSE2 oligonucleotide (comp.). Incubation time was 5 min. (E) High stability of the DCbfa1–OSE2 complex. EMSA was
performed with a fixed quantity of protein (GST–Cbfa1 or GST–DCbfa1), labeled OSE2, and a 100-fold molar excess of cold OSE2.
Incubation times in presence of competitor were as indicated.
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More importantly, this decrease in the bone formation
rate occurred while there was no decrease in osteoblast
and osteocyte numbers in the DCbfa1-expressing mice
(Fig. 4E–G). This indicates that the osteopenia induced
by the osteoblast-specific expression of DCbfa1 was
caused by a functional failure of the osteoblasts, not by
an absence or a depletion of the osteoblast population as
in the Cbfa1-deficient mice. The number of osteoclasts
was also identical in wild-type and transgenic animals
(Fig. 4H,I).
Taken together these results indicate that DCbfa1 was
interfering with a second function of Cbfa1, namely the
maintenance of bone formation by differentiated osteo-
blasts.
DCbfa1-expressing osteoblasts are less active
than wild-type osteoblasts
When put in culture osteoblastic cells synthesize type I
collagen and alkaline phosphatase whose presence can
be detected by colorimetric assays (Bancroft and Stevens
1996). Furthermore, following the synthesis of this col-
lagen-rich matrix these cells have the unique ability to
form compact nodules that become mineralized eventu-
ally (Aubin and Liu 1996; Stein et al. 1996). Thus, the
size and the very existence of nodules is a reflection of
the amount of extracellular matrix surrounding the cells.
To determine whether the cells identified in DCbfa1-
expressing mice as osteoblasts by morphologic criteria
were bona fide osteoblasts we established osteoblast cul-
ture from newborn calvaria of wild-type and DCbfa1-ex-
pressing mice. Cells from the transgenic animals did
form a collagen-rich matrix and mineralized nodules in-
Figure 2. Generation of DCbfa1-expressing mice. (A) Represen-
tation of the DCbfa1 transgene. (DBD) DNA-binding domain. (B)
RT–PCR showing DCbfa1 bone-specific expression in trans-
genic mice (arrow). Amplification of exon 2 of Hprt was used as
an internal control for cDNA quality and PCR efficiency in each
lane (bottom). (C) RT–PCR analysis comparing DCbfa1 level of
expression in the two independent transgenic lines analyzed in
this study (F21 and F28, top). RNAs were extracted from long
bones of 1-month-old mice. Amplification of exon 2 of Hprt was
used as an internal control for cDNA quality and PCR efficiency
in each lane (bottom). PCR reactions were performed in pres-
ence of [32P]dCTP. (D) Skeletal preparation of newborn wild-
type and DCbfa1-expressing mice. Note the presence of nor-
mally developed skull (arrowhead) and clavicles (arrow), exclud-
ing a CCD phenotype. No delayed or impaired mineralization is
visible at that stage unlike the case in the Cbfa1-deficient mice
(Komori et al. 1997; Otto et al. 1997).
Figure 3. Radiological and histological analysis of DCbfa1-ex-
pressing mice. (A–C) X-ray analysis of 2-week-old wild-type
(WT) and DCbfa1-expressing mice (DCbfa1). DCbfa1-expressing
mice are smaller and have shorter long bones with decreased
cortical thickness (arrows). (D) Histologic analysis of the growth
plate cartilage in tibia of 3-week-old wild-type and DCbfa1 lit-
termates. (E–H) Histologic analysis of cancellous (E,F,H) and
cortical (G) bone in 3-week-old wild-type and DCbfa1-express-
ing littermates. (E) Longitudinal sections through the tibia at
the metaphysis showing mineralized trabecular bone stained in
black by von Kossa and osteoid and cartilage counterstained in
pink with Kernechtrot. Brackets indicate the extend of calcified
bone matrix. (F) Longitudinal sections through the tibia at the
metaphysis stained with toluidine blue showing the decreased
amount of bone trabeculae (arrows) present in the DCbfa1-ex-
pressing mice. (G) Longitudinal sections through the tibia
stained by toluidine blue. Cortical thickness are indicated by
white arrows. (H) High magnification visualization of the os-
teoblasts (white arrows) present at the surface of the tibia tra-
beculae showing that they appear morphologically identical in
3-week-old wild-type and DCbfa1-expressing littermates. Note
that the osteoid layer present below the osteoblasts and staining
light blue (brackets) is significantly thinner in DCbfa1-express-
ing mice compared to wild-type littermates.
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dicating that they were functional osteoblasts (Fig. 5A–
C). However these nodules appeared smaller and less
compact than the one observed when using cells from
wild-type animals (Fig. 5A,B). The ECM synthetized by
the DCbfa1-expressing cells stained positively for colla-
gen and cellular alkaline phosphatase was detected but
again these stainings were weaker than the one observed
in wild-type nodules (Fig. 5B–D). Finally, von Kossa’s
staining for mineral showed that the ECM surrounding
the nodules generated using DCbfa1-expressing cells was
mineralized poorly compared to the one surrounding the
wild-type nodules (Fig. 5E,F). Thus, the results of these
Figure 4. Bone formation and cell param-
eters in DCbfa1-expressing mice. (A) Fluo-
rescent micrographs of the two labeled
mineralization fronts at the mid-diaphysis
of the tibiae of 3-week-old wild-type (WT)
and DCbfa1-expressing mice. The brackets
between the two labelings, tetracyclin at
the top and calcein at the bottom, indicate
the amount of newly formed bone. Note
the three- to four-fold decrease in the dis-
tance between the two labeled areas in
DCbfa1-expressing mice (B–D) Compari-
son of bone formation parameters in
3-week-old wild-type and DCbfa1-express-
ing mice. Measurement of bone formation
rate (B), osteoid thickness (C), and trabec-
ular bone volume (bone volume over total
volume, BV/TV) (D). (E–I) Comparison of
cell surfaces and numbers in 3-week-old
wild-type and DCbfa1-expressing mice.
(ObS) osteoblast surface; (BS) bone surface;
(NOb) number of osteoblasts; (Bpm) bone
perimeter (mm2); (OcS) osteoclast surface;
(NOc) number of osteoclasts. Bars repre-
sent means ± S.E.M. (*) Statistically signifi-
cant difference between wild-type and
transgenic mice groups (*) P < 0.05; n = 6.
Figure 5. Functional analysis of the osteoblasts de-
rived from DCbfa1 mice. Ex vivo culture of osteo-
blasts derived from calvaria of newborn wild-type and
DCbfa1-expressing mice were analyzed after 20 days
in presence of mineralization medium (see Materials
and Methods). (A) Goldner trichrome staining show-
ing that the DCbfa1-expressing osteoblasts form
smaller and fewer nodules (arrows). (B) van Gieson
staining for collagen (pink/purple color). Note the
lighter aspect of the matrix secreted by the DCbfa1-
expressing osteoblasts. (C) von Kossa staining show-
ing that the bone matrix secreted by the DCbfa1-ex-
pressing osteoblasts is mineralized poorly compared
to wild-type cultures. (D) Higher magnification of the
culture presented in B. There are fewer and smaller
collagen-secreting nodules in cultures derived from
DCbfa1-expressing mice than from their wild-type lit-
termates. (E) High magnification of cells stained for
alkaline phosphatase. DCbfa1-expressing osteoblasts
are synthetizing alkaline phosphatase (blue) but at a
lower level than wild-type mice. (F,G) von Kossa
staining for mineralized bone matrix. (F) Less miner-
alized nodules (arrows) are present in the DCbfa1-de-
rived cultures. (G) Higher magnification of the cul-
ture presented in F, photographied in polarized light.
The mineralized nodules (black) present in cultures
derived from DCbfa1-expressing mice are smaller
than the one derived from their wild-type littermates.
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functional ex vivo assays indicate that the bones of the
DCbfa1-expressing mice did contain functional osteo-
blasts but that these cells were less active than wild-type
osteoblasts. This is in full agreement with the result of
the histomorphometric analysis showing a normal num-
ber of osteoblasts but a decreased bone formation rate.
Decreased expression of the genes encoding the main
bone matrix proteins in DCbfa1-expressing mice
In the presence of a normal number of osteoblasts an
osteopenia could develop only if each osteoblast is pro-
ducing less of the various proteins required to form the
bone ECM. Accordingly, the expression of the two genes
encoding osteocalcin (OG1 and OG2) (Desbois et al.
1994), the most abundant noncollagenous protein
(Hauschka et al. 1989), of Bone sialo protein, another
osteoblast-specific gene (Bianco et al. 1991), and of Os-
teopontin (Denhardt and Guo 1993), were all decreased
severely in 2- and 4-week-old DCbfa1-expressing mice
(Figs. 6A and 7C, below). These proteins account for only
10% of the protein content of the bone ECM, therefore
the decreased expression of these genes alone could not
explain the osteopenic phenotype of the DCbfa1-express-
ing mice. Type I collagen is the most abundant constitu-
ent of the bone matrix, accounting for 90% of the bone
protein content. It has been largely demonstrated that its
integrity is required for proper bone formation and for
skeleton growth postnatally (Prockop and Kivirikko
1984; Byers 1990; Rowe and Shapiro 1998). The expres-
sion of a1(I) and a2(I) collagen, the two genes encoding
type I collagen, was decreased markedly in DCbfa1-ex-
pressing mice compared to wild-type littermates (Fig.
6A). The expression of Hprt was not affected in the
DCbfa1-expressing mice indicating that the effects we
observed were specific. The expression of a1(I) collagen
was not reduced in skin fibroblasts of the DCbfa1-ex-
pressing mice (Fig. 6B) further demonstrating the speci-
ficity of the abnormalities observed in the bones of these
animals.
Evolution of the phenotype of DCbfa1-expressing
mice
The activity of the OG2 promoter fragment used to drive
DCbfa1 is dependent partly for its expression on two
OSE2 elements (Ducy and Karsenty 1995; Frendo et al.
1998). Given the higher affinity of DCbfa1 than Cbfa1 for
DNA, one would predict that at one point the level of
expression of the transgene should decrease. Its expres-
sion should not be abolished because of the presence in
this promoter fragment of OSE1, another osteoblast-spe-
cific element (Fig. 7A). Consistent with this model we
could observe a histological phenotype for the first 4
weeks of life of the DCbfa1-expressing animals (Fig. 7B).
Beyond 4 weeks the phenotype faded and the mice had a
normal life span (Fig. 7B). Likewise, the expression of the
bone matrix genes was nearly abolished at 2 weeks of
age, decreased at 4 weeks of age, and was normal in older
animals (Figs. 6A and 7C). As expected, the expression of
the transgene peaked at 2 weeks and decreased thereafter
(Fig. 7D).
Down-regulation of Cbfa1 expression
in DCbfa1-expressing mice
The near complete abolition of osteoblast-specific gene
expression observed in the DCbfa1-expressing mice
could be explained by a combination of several mecha-
nisms: The level of expression of the transgene could be
extremely high, DCbfa1 could bind to DNA with a
higher affinity than full-length Cbfa1, and/or Cbfa1
could regulate its own expression. Comparison of the
transgene and endogenous gene levels of expression re-
vealed that they were similar (Fig. 8A), thus ruling out
the first mechanism. As shown in Figure 1, D and E,
DCbfa1 bound DNA with a higher affinity for OSE2 than
the full-length Cbfa1, and the DCbfa1–DNA complex
was more stable than the Cbfa1–DNA complex. This
provided one molecular explanation for the progression
of the phenotype.
To search for additional explanations we studied en-
dogenous Cbfa1 expression in DCbfa1-expressing mice.
Endogenous Cbfa1 expression was nearly abolished in
every transgenic mouse analyzed at 2 weeks of age (Fig.
8B), implying that Cbfa1 controls its own expression.
Sequence inspection of the 58 region of the Cbfa1 mouse
and human genes showed the presence of three con-
served consensus OSE2 sites that were analyzed further
(Fig. 8C). In EMSA, osteoblast nuclear extracts bound to
oligonucleotides containing these OSE2 elements, an an-
tibody against Cbfa1 caused an upward shift of the pro-
Figure 6. Osteoblast gene expression in DCbfa1-expressing
mice. (A) RT–PCR analysis of gene expression in long bones of
2-week-old wild-type (wt) and DCbfa1-expressing mice. Ampli-
fication of exon 2 of Hprt was used as an internal control for
cDNA quality and PCR efficiency in each lane. Expression of
Osteocalcin, Bsp, and Osteopontin is virtually abolished,
whereas expression of a1(I)collagen is reduced markedly, and
the expresssion of a2(I)collagen is reduced moderately. (B)
Northern blot analysis of a1(I)collagen expression in skin of
2-week-old wild-type and DCbfa1-expressing mice. The Gapdh
cDNA was used to reprobe this Northern blot to assess equal
loadings in the different lanes (bottom).
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tein–DNA complex (Fig. 8D), and recombinant Cbfa1
bound to the wild-type oligonucleotides but not to their
mutated counterparts (Fig. 8E). Finally, in DNA cotrans-
fection experiments exogenous Cbfa1 transactivated a
Cbfa1 promoter–luc chimeric gene containing wild-type
OSE2 elements but not a similar construct containing
mutant OSE2 elements (Fig. 8F). Taken together these
experiments, along with the near abolition of Cbfa1 ex-
pression in DCbfa1-expressing mice, demonstrate that
those elements are bona fide OSE2s, and that Cbfa1 is a
positive regulator of its own expression.
Remarkably, quantitative DNA-binding assays per-
formed with decreasing amounts of recombinant Cbfa1
and a fixed quantity of probes demonstrated that Cbfa1
had a 10- to 100-fold higher affinity for the OSE2 ele-
ments in Cbfa1 than for any other known OSE2 element
(Fig. 9). It is interesting to note that the OSE2 site with
the lowest affinity for Cbfa1 is located in a2(I) collagen,
the gene whose expression was the least affected in the
DCbfa1-expressing mice (Fig. 6A). This 100:1 order of
magnitude higher affinity of Cbfa1 for the sites present
in the Cbfa1 promoter than for any other sites most
likely contributed to the severity of the phenotype ob-
served in the DCbfa1-expressing mice and emphasizes
the importance of this autoregulatory loop as a critical
means through which Cbfa1 controls structural gene ex-
pression and thereby bone formation by differentiated
osteoblasts.
Discussion
Our study uncovers a genetic cascade with Cbfa1 at its
origin that controls bone formation after osteoblast dif-
ferentiation is achieved. It illustrates that developmen-
tally important genes may have additional and critical
roles beyond embryonic development.
Bone formation is a different process
than bone development
Bone ECM deposition by differentiated osteoblasts, or
bone formation, occurs throughout life and fulfills sev-
eral physiological functions after birth. During postnatal
development, bone formation is required during endo-
chondral ossification to replace the cartilagenous tem-
plates near the growth plate cartilage thereby ensuring
proper longitudinal bone growth. During adulthood bone
formation in the context of bone remodeling must be
regulated tightly to replace the bone resorbed by the os-
teoclasts to maintain a near constant bone mass. Thus,
any qualitative or quantitative defect of the osteoblasts,
inherited or acquired, could result in short stature, bone
fragility, and/or osteoporosis, the most frequent meta-
bolic bone disease. These multiple requirements under-
score the need to understand the molecular basis of bone
formation by the osteoblasts and to identify molecule(s)
regulating this function.
Figure 7. Auto-down-regulation of the
DCbfa1 transgene and transient aspect of
the osteopenic phenotype in DCbfa1-ex-
pressing mice. (A) Functional organization
of the 1.3-kb OG2 promoter. The OSE1 site
and the two OSE2 sites are indicated by
open and solid boxes, respectively. (B) His-
tological analysis of long bones (tibiae) of
2-, 4-, and 8-week-old wild-type and
DCbfa1-expressing mice. Sections through
the metaphyses stained with hematoxylin/
eosin. The amount of trabecular bone
(pink, arrows) is severely decreased in
2-week-old trangenic mice and return to
normal in 8-week-old animals. (C) RT–
PCR analysis of ECM protein-encoding
gene expression in long bones of 4- and
8-week-old wild-type and DCbfa1-express-
ing mice. Expression of Osteocalcin, Bone
sialo protein, Osteopontin, a1(I)collagen,
and a2(I)collagen in the transgenic mice is
still decreased in 4-week-old animals, but
less than that in 2-week-old mice (cf. with
Fig. 6A), and returns to normal in 8-week-
old mice. Amplification of exon 2 of Hprt
was used as an internal control for cDNA
quality and PCR efficiency in each lane.
(D) Temporal analysis of DCbfa1 expres-
sion in transgenic animals. Expression of
the transgene peaks at 2 weeks of age and is
decreased severely thereafter. Amplifica-
tion of exon 2 of Hprt was used as an in-
ternal control for cDNA quality and PCR
efficiency in each lane.
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Mouse and human genetic studies have demonstrated
that the integrity of structural proteins of the skeleton is
critical for a proper bone formation. Mutations in either
one of the two genes encoding type I collagen cause os-
teogenesis imperfecta (OI), a disease characterized by a
decrease in bone formation and whose severity can vary
from lethal forms to osteoporosis-like phenotypes
(Prockop and Kivirikko 1984; Byers 1990). The potential
severity of the OI phenotype is consistent with the abun-
dance of type I collagen in bone matrix. Likewise, ge-
netic analyses have uncovered the role of noncollag-
enous proteins such as alkaline phosphatase, Bone sialo
protein, Osteocalcin, Osteopontin, and Fibrillin, among
others, as regulators of bone matrix deposition, matrix
mineralization, osteoclast function, and tensile strength
of the bones (J.E. Aubin, pers. comm.; Ducy et al. 1996;
Pereira et al. 1997; Rittling et al. 1998). Taken together,
these molecules are the effectors of the osteoblasts’ func-
tion. However, what remains to be identified is/are regu-
lator(s) of osteoblast function.
Cbfa1 is a regulator of osteoblast function
Because of its expression in differentiated osteoblasts
postnatally and its role in regulating Osteocalcin (Ducy
et al. 1997), the latest gene to be expressed in osteoblasts
(Owen et al. 1990; Stein et al. 1990; Aubin and Liu 1996),
we hypothesized that Cbfa1 could regulate bone forma-
tion and used a dominant-negative approach to test this
hypothesis. Three lines of evidence indicate that Cbfa1
is the only Cbfa protein present in osteoblasts in vivo.
First, in situ hybridization and Western analyses failed to
detect Cbfa2 or Cbfa3 in osteoblasts (Simeone et al.
1995; Wijmenga et al. 1995; Ducy et al. 1997; this study).
Figure 9. Different affinities of various OSE2s for GST–Cbfa1.
Labeled OSE2s present in the Cbfa1, Osteocalcin, and type I
collagen promoters were used as probes in EMSA with decreas-
ing amount of recombinant protein as expressed by arbitrary
units. A binding unit is defined as the quantity of GST–Cbfa1
required to shift 50% of the Osteocalcin promoter OSE2a probe,
the initial OSE2 element described (Ducy and Karsenty 1995).
GST–Cbfa1 has a 10- and 100-fold higher affinity for Cbfa1
OSE2s than for the Osteocalcin and type I collagen genes
OSE2s, respectively.
Figure 8. Characterization of Cbfa1 au-
toregulation. (A) RT–PCR analysis com-
paring the DCbfa1 transgene (top) and en-
dogenous Cbfa1 (bottom) levels of expres-
sion in long bones of 2-day-old transgenic
mice. (B) Down-regulation of Cbfa1 ex-
pression in 2-week-old DCbfa1 compared
to wild-type (WT) mice. RT–PCR analysis
of gene expression in long bones of
2-week-old wild-type and DCbfa1-ex-
pressing mice. Amplification of exon 2 of
Hprt was used as an internal control for
cDNA quality and PCR efficiency in each
lane. (C) Presence of three identical OSE2
elements (shaded boxes) in the promoter
of the mouse and human Cbfa1 genes. (D)
Binding in EMSA of ROS 17/2.8 nuclear
extracts to the OSE2 elements present in
Cbfa1. The specific protein–DNA com-
plex (arrow) is supershifted by preincuba-
tion with an antiserum against Cbfa1. (E)
Binding in EMSA of GST–Cbfa1 to the
wild-type (wt) but not the mutated (mut)
versions of the OSE2s present in Cbfa1.
(F) Functional characterization of the
Cbfa1 OSE2 elements. Activation of the
Cbfa1 promoter containing wild-type
OSE2 elements upon cotransfection with
a Cbfa1 expression vector in COS cells.
Mutation of the OSE2 elements inhibits
this effect.
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Second, we and others have failed to identify new Cbfa
genes expressed in the skeleton. Third and more impor-
tantly, deletion of the Cbfa1 gene led to a complete ab-
sence of osteoblast in homozygous mutant mice indicat-
ing that no other transcription factor can fulfill Cbfa1’s
regulatory function during osteoblast differentiation (Ko-
mori et al. 1997; Otto et al. 1997) Thus, the phenotype
observed in the DCbfa1-expressing mice is caused by a
specific inhibition of Cbfa1 function.
To demonstrate a second function for Cbfa1 in differ-
entiated osteoblasts, distinct from its function during
osteoblast differentiation, we took advantage of the Os-
teocalcin promoter which is active only in differentiated
osteoblasts able to produce a matrix (Owen et al. 1990;
Stein et al. 1990; Aubin and Liu 1996; Frendo et al. 1998).
The results of this study demonstrate that Cbfa1 con-
trols bone formation by differentiated osteoblasts. Cbfa1
is at the top of a genetic cascade controlling positively its
own expression and the expression of the major osteo-
blast-specific and osteoblast-enriched genes through its
binding to multiple OSE2 elements present in these
genes (Fig. 9). This autoregulatory loop of Cbfa1 expres-
sion is so critical for proper bone formation because
Cbfa1 has a much higher affinity for its binding sites in
Cbfa1 than for any other known binding sites. It is pos-
sible that other OSE2 elements present elsewhere in
Cbfa1 could play an additional role in the autoregulation
of Cbfa1 expression and in the severity of the phenotype
of the DCbfa1-expressing mice. This autoregulatory loop
of Cbfa1 expression could also be important during de-
velopment to maintain osteoblast differentiation once it
is initiated. Our findings distinguish Cbfa1 from other
molecules such as the bone morphogenetic proteins
(BMPs) (Hogan 1996) that can induce bone formation by
recapitulating all the cell differentiation events occur-
ring during skeleton development. Instead, Cbfa1 acts as
a maintenance factor of the differentiated osteoblasts by
simply regulating the rate of bone matrix deposition by
already differentiated cells.
In light of the absence of reported juvenile or more
severe osteoporosis in CCD patients the phenotype we
observed is unexpected. This is likely because of the
more severe decrease of expression of the genes encoding
bone ECM proteins, notably type I collagen, in the
DCbfa1-expressing mice compared to the heterozygous
Cbfa1-deficient mice. Figure 10 summarizes the two as-
pects of Cbfa1 function: During embryonic development
Cbfa1 controls cell differentiation along the osteoblastic
pathway, postnatally Cbfa1 has an additional function, it
controls directly bone matrix deposition by differenti-
ated osteoblasts.
Cbfa1 as a tool to study bone remodeling
This second function of Cbfa1 has important biological
implications. First, some skeletal features observed in
CCD patients like short stature, growth retardation, and
abnormally shaped epiphyses and metaphyses (Marie
and Santon 1898; Soule 1946) have long been viewed as
proof that the CCD gene has a role during postnatal skel-
etal growth (Mundlos and Olsen 1997). These features
can now be explained by the fact that Cbfa1 control bone
formation by differentiated osteoblasts postnatally. Sec-
ond, this study raises the possibility that mutations in
the Cbfa1 gene that leave intact the DNA-binding do-
main of Cbfa1 but affect its transactivation function may
result in slightly more severe postnatal manifestations
in CCD patients. More generally, mutations affecting
one of the transactivation domains of Cbfa1 (Thiruna-
vukkarasu et al. 1998) could be at the origin of some
form of genetically inherited low or high bone mass dis-
eases. The ability of Cbfa1 to control the function of
already differentiated osteoblasts, together with the fact
that haploinsufficiency at the Cbfa1 locus is at the origin
of CCD (Lee et al. 1997; Mundlos et al. 1997; Otto et al.
1997), raises the hypothesis that increasing Cbfa1 rate of
transcription in elder individuals may be a way to pre-
vent or to treat osteopenic diseases. This warrants fur-
ther investigation of the already established regulation of
Cbfa1 expression by growth factors and hormones (Ducy
et al. 1997) (Fig. 10). Lastly, this study along with the
recent characterization of the role of osteoprotegerin and
its ligand during bone resorption (Simonet et al. 1997;
Lacey et al. 1998; Yasuda et al. 1998) provides some of
the molecular tools that are necessary to understand the
mechanisms controlling the maintenance of a near con-
stant bone mass through bone remodeling during adult-
hood.
Figure 10. Schematic representation of Cbfa1 function dur-
ing and after embryonic development. (A) During embryo-
genesis Cbfa1 controls differentiation of a mesenchymal pro-
genitor cell toward the osteoblastic lineage. (B) After birth,
in fully differentiated osteoblasts, Cbfa1 controls the rate of
bone formation by regulating directly the expression of the
bone ECM-encoding genes. Moreover, Cbfa1 regulates its
own gene expression.
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Beyond the involvment of Cbfa1 in bone formation a
more general implication of these results is that other
genes that play critical roles during embryonic develop-
ment and that are also expressed after birth could also be
involved during physiological processes postnatally. For
instance, it is tempting to speculate that this function of
Cbfa1 in cell physiology may be a feature shared by
many transcriptional activators of cell differentiation;
the easy-to-score nature of bone formation providing a
favorable setting to uncover this aspect of their biology.
Materials and methods
DNA construction and generation of transgenic mice
For DNA transfections the 396-bp NcoI–HindIII fragment of
Cbfa1 encoding the DNA-binding domain was cloned into the
pEFBOS expression vector (Mizumisha and Nagata 1990).
DCbfa1 transgenic mice bear a fusion gene composed of a 1.3-kb
fragment of the mouse OG2 promoter (Ducy and Karsenty 1995)
fused to Cbfa1 DNA-binding domain and the 38 untranslated
and polyA signal of the human G-CSF cDNA (Nagata et al.
1986). Transgenic founders were generated by pronuclear injec-
tion according to standard techniques (Bonnerot and Nicolas
1993). Genotype of transgenic animals was determined by PCR
using as primers 58-CGGAGCGGACGAGGCAAGAGTTTC-38
and 58-ACGGTGGGGAAGACTGTCCTGCCTG-38. To gener-
ate prokaryotic expression vectors the AcyI–HincII fragment
and the NcoI–HindIII fragment of the Cbfa1 cDNA, encoding
the full-length protein and the DNA-binding domain, respec-
tively, were ligated in-frame with the GST-coding sequence of
the pGEX-4T3 vector (Pharmacia). Luc chimeric constructs
were generated by cloning multimerized oligonucleotides or
promoter fragments in the pA3luc vector (Goldberg et al. 1992).
Mutagenesis of the Cbfa1 promoter was performed by PCR am-




The pCMV5 expression vector (Andersson et al. 1989) empty or
containing the Osf2/Cbfa1 (Ducy et al. 1997), Cbfa2 (Bae et al.
1992), or Cbfa3 (Bae et al. 1995) cDNAs was transfected in COS
cells. Nuclear extracts were prepared 24 hr later as described
(Ducy and Karsenty 1995). Nuclear extracts from mouse cal-
varia were prepared according Deryckere and Gannon (1994).
SDS-PAGE and immunoblotting were performed according
standard procedures (Ausubel et al. 1995) using an antiserum
against the peptide SFFWDPSTSRRFSPPS and the ECL detec-
tion kit (Amersham).
DNA-binding assays
Labeling of oligonucleotide probes, EMSA, and supershift assays
were done as described (Ducy and Karsenty 1995; Ducy et al.
1997). Each experiment was repeated at least three times. GST-
tagged proteins were enriched according to standard protocols
(Ausubel et al. 1995). Nuclear extracts were prepared as de-
scribed previously (Ducy and Karsenty 1995). Top-strand se-








and a1(I)OSE2 oligonucleotides have been described elsewhere
(Ducy and Karsenty 1995; Ducy et al. 1997; Frendo et al. 1998).
Morphological and histological analyses
Skeletons from newborn pups were prepared as described
(Kochhar 1973) and stained with alcian blue 8GX and alizarin
red S. For histological analysis mice were sacrificed at 2, 3, 4,
and 8 weeks of age. For assessment of dynamic histomorpho-
metric indices, mice of the 3-week group were injected with
tetracyclin and calcein 10 and 2 days, respectively prior to sac-
rifices, according to standard tetracyclin/calcein double-label-
ing procedure (Vignery and Baron 1980). After radiological
analysis of the skeleton (Faxitron, Munich, Germany), long
bones and vertebrae were dissected out and fixed in 4% form-
aldehyde for 18 hr at 4°C. Undecalcified bones were embedded
in methylmethacrylate, and 5-µm sections were prepared on a
rotation microtome (Jung, Heidelberg, Germany) as described
previously (Hahn et al. 1991; Amling et al. 1997). Sections were
stained with 1% toluidine blue, or von Kossa reagent (3% silver
nitrate counterstained with Kernechtrot), or hematoxylin/eo-
sin, and evaluated using a Zeiss microscope (Carl Zeiss, Jena,
Germany). Histomorphometrical analysis was performed on
tibiae and vertebrae according to the American Society for Bone
and Mineral Research (ASBMR) standards (Parfitt et al. 1987)
using the OsteoMeasure Analysis System (Osteometrix, At-
lanta, GA). Statistical differences between groups were assessed
by Student’s t-test. Histology and histomorphometry data
shown in Figures 3 and 4 were obtained from tibia metaphyses.
Ex vivo experiments
Osteoblasts from individual calvaria of newborn wild-type
(n = 4) or transgenic (n = 4) pups were isolated according to the
following protocol. After incubation for 40 min in aMEM-0.1
mg/ml collagenase P–2.5% trypsin at 37°C, shaking, calvaria
were washed in aMEM, cut in pieces and transfered in aMEM-
0.1 mg/ml collagenase P-10% trypsin for 1 hr at 37°C and
shook. Digestion was stopped by addition of 10 volumes of
aMEM/10% FBS. The cells were allowed to attach for 48 hr and
were then replated at a density of 12,000 cells per cm2 in
aMEM/10% FBS for 2 days. Thereafter the medium was supple-
mented with 5 mM b-glycerophosphate and 100 µg/ml ascorbic
acid (mineralization medium) and replaced every 2 days. Cul-
tures were maintained for 20 days before analysis for alkaline
phosphatase and collagen synthesis (van Gieson staining), and
for presence of a mineralized matrix (Goldner trichrome and
von Kossa staining) according to standard protocols (Bancroft
and Stevens 1996).
RT–PCR analysis
For RNA preparation long bones were dissected free of sur-
rounding tissues. Epiphyses were cut out and the bone marrow
flushed. Three to four animals were analyzed independently.
We used RT–PCR to analyze variations of gene expression be-
tween individual wild-type and transgenic animals because the
amount of RNA obtained per animal prevented us to perform
Northern blot analyses. RNA extraction, cDNA synthesis, and
PCR amplification were performed using standard protocols
(Ausubel et al. 1995). Exon 2 amplification of the Hprt gene was
used as internal control for the quantity and quality of cDNAs.
The following sets of primer were used: DCbfa1, 58-CAGCAGT-
Ducy et al.
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GTTCCCCATCTGGGTCCT-38 and 58-GGGGGGTGAAGA-
GGTGGAGGGTGAC-38; Hprt, 58-GTTGAGAGATCATCTC-
CACC-38 and 58-AGCGATGATGAACCAGGTTA-38; Osteo-




and 58-GTCATCACCTCGGCCGTTGGGG-38; a1(I) collagen,
58-CCTGGTAAAGATGGTGCC-38 and 58-CACCAGGTTCA-
CCTTTCGCACC-38; a2(I) collagen, 58-TGGTCCTCTGGGC-
ATCTCAGGC-38 and 58-GGTGAACCTGCTGTTGCCCTCA-
38; Cbfa1, 58-GAGGCCGCCGCACGACAACCGCA-38 and 58-
ACGGTGGGGAAGACTGTCCTGCCTG-38.
DNA transfections and luc assays
ROS 17/2.8 osteoblastic cells were transfected with increasing
amount of expression vector, 5 µg of luc reporter vector and 2 µg
of pSVbgal plasmid. COS cells were transfected with 5 µg of
expression vector, 5 µg of luc reporter vector and 2 µg of pSVbgal
plasmid. Transfection, luc assays, and b-galactosidase assays
were performed as described (Ducy and Karsenty 1995). Data
represent ratios of luc/b-galactosidase activities and values are
means of six to eight independent transfection experiments;
error bars represent standard deviation of the means.
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